Oppenheimer analyst Jeff Jones raised the firm’s price target on Corvus Pharmaceuticals (CRVS) to $14 from $8 and keeps an Outperform rating on the shares following quarterly results. The firm is highly encouraged by management’s enthusiasm for the upcoming atopic dermatitis readout in December. Cash remains constrained given the level of clinical activity, with Q3-ending cash reported at $42M, providing runway into early 2026, by Oppenheimer’s estimate.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRVS:
- Corvus Pharmaceuticals Reports Q3 2024 Financial Results
- Corvus Pharmaceuticals reports Q3 EPS (60c), consensus (11c)
- Corvus Pharmaceuticals options imply 17.7% move in share price post-earnings
- Corvus Pharmaceuticals options imply 12.0% move in share price post-earnings
- Is CRVS a Buy, Before Earnings?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
